Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, and HER2/EGFR in Cancer Research.
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
The Integration of Clinical Trials With the Practice of Medicine
Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for Evidence
Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Adaptive Randomization of Neratinib in Early Breast Cancer
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer